We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 31, 2021

Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years

MMWR. Morbidity and Mortality Weekly Report

 

Additional Info

Disclosure statements are available on the authors' profiles:

MMWR. Morbidity and Mortality Weekly Report
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021
MMWR Morb. Mortal. Wkly. Rep. 2021 May 21;70(20)749-752, M Wallace, KR Woodworth, JW Gargano, et al

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading